Complete transgene integration site characterization for producer cell banks and immunotherapy products with TLA technology

In this webinar, recorded November 12 2020, we present the advantages of TLA in both the upstream and downstream processes of cell and gene therapy manufacturing. 

The following subjects are highlighted:

  • Principles of TLA technology
  • Viral vector producing MCB characterization
  • Characterization of immunotherapy products

For an overview of the publications cited in the presentation, click here for cell and gene therapy.

Please contact us for more information.



© 2012-2021 Cergentis B.V. All rights reserved.
For Research Use Only.Not for use in diagnostic procedures.
We use cookies for website analysis and marketing. By visiting and using our website you accept these cookies.